Triglyceride-Glucose Index in Diabetic Nephropathy in Type 2diaberes Mellitus Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05602532

Enrollment

100

Registered

2022-11-02

Start date

2022-11-01

Completion date

2023-10-01

Last updated

2022-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Brief summary

The aim of the present study is to investigate the associations between the TyG index and diabetic nephropathy in patients with type2 DM .

Detailed description

the triglyceride-glucose (TyG) index was proposed as a simple and reliable surrogate marker of IR, and it has been reported to be closely correlated with the HOMA-IR index. The TyG index has the advantage of being applicable in clinical practice since both triglyceride and glucose levels are routinely measured and the cost of these measurements is low.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to 75 Years

Inclusion criteria

* patients with type 2 DM

Exclusion criteria

\- (1) Individuals with obstructive uropathy, severe heart failure, stroke, liver disease, cancer, autoimmune disease (2) Pregnant woman. (3)End stage renal disease patients on dialysis ( glomerular filtration rate \<15 mL/min/1.73 m2) or renal transplantation. (4) Type 1 Diabetic patient. (5) Albuminuria due to non-diabetic renal disease

Design outcomes

Primary

Measure	Time frame	Description
TyG index in type 2diaberes Mellitus	Baseline	Detecting the association between the TyG index and diabetic nephropathy in type 2 diabetes

Contacts

Primary ContactAya Abo Eyosr Garhey

Ayayosry285@gmail.com01092606888

Backup ContactSalah Abdelazeem Argoon

Argoons@yahoo.com01019683366

Outcome results